ARS Pharmaceuticals (SPRY) Interest Coverage Ratio (2026)
ARS Pharmaceuticals recorded quarterly Interest Coverage Ratio of 24.64 in Q1 2026.
ARS Pharmaceuticals' Interest Coverage Ratio history runs 1 years deep, the most recent figure standing at 24.64 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio changed N/A year-over-year to 24.64; the TTM figure through Mar 2026 stood at 24.15 (changed N/A YoY), while the FY2025 annual figure was 13.85, changed N/A from the prior year.
- Interest Coverage Ratio came in at 24.64 for Q1 2026 at ARS Pharmaceuticals.
- In the past five years, Interest Coverage Ratio ranged from a high of 24.64 in Q1 2026 to a low of 24.64 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | ARS Pharmaceuticals | 900.62 Mn | 699.65 Mn | - | -24.64 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.64 |